{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:23:44Z","timestamp":1792254224496,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171167"],"award-info":[{"award-number":["32171167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dmd.2025.100136","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T23:47:22Z","timestamp":1753832842000},"page":"100136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling hepatic Kr\u00fcppel-like factor 15 as the key regulator of cyclosporine A metabolism and adverse effects"],"prefix":"10.1016","volume":"53","author":[{"given":"Xiaohua","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangxin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ku-Geng","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dmd.2025.100136_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02484-2020","article-title":"Cyclosporine: an old weapon in the fight against coronaviruses","volume":"56","author":"Molyvdas","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.dmd.2025.100136_bib2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s13346-019-00650-1","article-title":"Recent advances in cyclosporine drug delivery: challenges and opportunities","volume":"9","author":"Patel","year":"2019","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"10.1016\/j.dmd.2025.100136_bib3","article-title":"Cyclosporine for treating rheumatoid arthritis","volume":"2010","author":"Wells","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib4","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.dmd.2025.100136_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"10.1016\/j.dmd.2025.100136_bib7","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1021\/acsnano.3c11514","article-title":"Nanoceria-mediated cyclosporin A delivery for dry eye disease management through modulating immune\u2013epithelial crosstalk","volume":"18","author":"Cui","year":"2024","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.dmd.2025.100136_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2025.100136_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110633","article-title":"Occurrence and influencing factors of cyclosporine A on the kidney injury following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"122","author":"Lu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41401-022-00925-3","article-title":"Long-term treatment with the mPXR agonist PCN promotes hepatomegaly and lipid accumulation without hepatocyte proliferation in mice","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"20","key":"10.1016\/j.dmd.2025.100136_bib11","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","article-title":"Cyclosporine A: chemistry and toxicity\u2013a review","volume":"28","author":"Patocka","year":"2021","journal-title":"Curr Med Chem"},{"issue":"3","key":"10.1016\/j.dmd.2025.100136_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/taap.1999.8887","article-title":"Mechanisms of cyclosporine A-induced apoptosis in rat hepatocyte primary cultures","volume":"163","author":"Grub","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100136_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1389200219666181031113505","article-title":"Metabolic pathway of cyclosporine A and its correlation with nephrotoxicity","volume":"20","author":"Wu","year":"2019","journal-title":"Curr Drug Metab"},{"issue":"4","key":"10.1016\/j.dmd.2025.100136_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cmet.2007.03.002","article-title":"Regulation of gluconeogenesis by Kr\u00fcppel-like factor 15","volume":"5","author":"Gray","year":"2007","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.dmd.2025.100136_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cmet.2012.01.020","article-title":"Klf15 orchestrates circadian nitrogen homeostasis","volume":"15","author":"Jeyaraj","year":"2012","journal-title":"Cell Metab"},{"issue":"17","key":"10.1016\/j.dmd.2025.100136_bib16","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.1121060109","article-title":"Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation","volume":"109","author":"Haldar","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.dmd.2025.100136_bib17","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.celrep.2016.07.069","article-title":"KLF15 enables rapid switching between lipogenesis and gluconeogenesis during fasting","volume":"16","author":"Takeuchi","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.dmd.2025.100136_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s42255-019-0054-7","article-title":"KLF15 regulates endobiotic and xenobiotic metabolism","volume":"1","author":"Han","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.dmd.2025.100136_bib19","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1038\/ncomms8231","article-title":"Circadian control of bile acid synthesis by a KLF15-Fgf15 axis","volume":"6","author":"Han","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.dmd.2025.100136_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.123.001617","article-title":"KLF15-Cyp3a11 axis regulates rifampicin-induced liver injury","volume":"52","author":"Hou","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/hep.23984","article-title":"Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice","volume":"53","author":"Csanaky","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dmd.2025.100136_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2011.130","article-title":"In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients","volume":"90","author":"de Jonge","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmd.2025.100136_bib23","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.13934","article-title":"Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers","volume":"85","author":"Brings","year":"2019","journal-title":"Brit J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/toxsci\/kfp094","article-title":"Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice","volume":"110","author":"Cui","year":"2009","journal-title":"Toxicol Sci"},{"issue":"8","key":"10.1016\/j.dmd.2025.100136_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00592-021-01681-2","article-title":"Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy","volume":"58","author":"Castoldi","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.dmd.2025.100136_bib26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bcp.2019.03.022","article-title":"Modulation of innate immunity by cyclosporine A","volume":"163","author":"Liddicoat","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100136_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15490","article-title":"A systematic review of the efficacy and safety of topical cyclosporine in dermatology","volume":"35","author":"Sadeghi","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2025.100136_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5414\/CP202042","article-title":"Association of CYP3A4\u221718B and CYP3A5\u22173 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients","volume":"52","author":"Xin","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100136_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104562","article-title":"The effect of cyclosporine and the consequences in hepatic and renal function following ischemic stroke in a rats' model","volume":"29","author":"Dimopoulos","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"10.1016\/j.dmd.2025.100136_bib30","first-page":"227","article-title":"Drug interactions with cyclosporine-rifampicin-clarithromycin in a kidney transplant recipient with mycobacterium malmoense","volume":"4","author":"Perona","year":"2013","journal-title":"J Med Cases"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/j.1875-9114.1991.tb03603.x","article-title":"Rifampin and ansamycin interactions with cyclosporine after renal transplantation","volume":"11","author":"Vandevelde","year":"1991","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.dmd.2025.100136_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000183583","article-title":"Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient","volume":"41","author":"Cassidy","year":"1985","journal-title":"Nephron"},{"key":"10.1016\/j.dmd.2025.100136_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037814","article-title":"Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review","volume":"13","author":"Zhuang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100136_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.dmd.2025.100136_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/156802612799436678","article-title":"Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders","volume":"12","author":"Fiorucci","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"10.1016\/j.dmd.2025.100136_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.dmd.2025.100136_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nm815","article-title":"The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4","volume":"9","author":"Tirona","year":"2003","journal-title":"Nat Med"},{"issue":"6794","key":"10.1016\/j.dmd.2025.100136_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/35019116","article-title":"Humanized xenobiotic response in mice expressing nuclear receptor SXR","volume":"406","author":"Xie","year":"2000","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.dmd.2025.100136_bib39","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1074\/jbc.M511116200","article-title":"A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway","volume":"281","author":"Zhou","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2025.100136_bib40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nm.3104","article-title":"Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy","volume":"19","author":"Li","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.dmd.2025.100136_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-9-46","article-title":"Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation","volume":"9","author":"Raynal","year":"2010","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol Cancer"},{"issue":"9203","key":"10.1016\/j.dmd.2025.100136_bib43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0140-6736(99)05467-7","article-title":"Acute heart transplant rejection due to Saint John's wort","volume":"355","author":"Ruschitzka","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.dmd.2025.100136_bib44","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1124\/dmd.109.027565","article-title":"Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity","volume":"37","author":"Cheng","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100136_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41419-018-0875-4","article-title":"Poly(ADP-ribosyl)ated PXR is a critical regulator of acetaminophen-induced hepatotoxicity","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Disease"},{"issue":"5592","key":"10.1016\/j.dmd.2025.100136_bib46","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1126\/science.1073502","article-title":"Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR","volume":"298","author":"Zhang","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.dmd.2025.100136_bib47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jgh.16812","article-title":"The ubiquitination degradation of KLF15 mediated by WSB2 promotes lipogenesis and progression of hepatocellular carcinoma via inhibiting PDLIM2 expression","volume":"40","author":"Chen","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dmd.2025.100136_bib48","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front Med"},{"issue":"21","key":"10.1016\/j.dmd.2025.100136_bib49","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.dmd.2025.100136_bib50","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:26:55Z","timestamp":1772818015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0090955625091457"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100136","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling hepatic Kr\u00fcppel-like factor 15 as the key regulator of cyclosporine A metabolism and adverse effects","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100136"}}